[Skip to Content]
[Skip to Content Landing]
Research Letter
September 30, 2019

Trends in Aggregate Use and Associated Expenditures of Antihyperglycemic Therapies Among US Medicare Beneficiaries Between 2012 and 2017

Author Affiliations
  • 1Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas
  • 2Brigham and Women’s Hospital Heart and Vascular Center, Harvard Medical School, Boston, Massachusetts
  • 3Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas
  • 4Ahmanson-UCLA Cardiomyopathy Center, University of California, Los Angeles, Los Angeles
  • 5Department of Medicine, University of Mississippi Medical Center, Jackson
JAMA Intern Med. 2020;180(1):141-144. doi:10.1001/jamainternmed.2019.3884

There are now 12 classes of antihyperglycemic medications available for patients with type 2 diabetes mellitus (DM). With an estimated 30 million patients in the United States living with DM1 and increasing complexity and financial burden of DM care, the relative distribution of expenditures across DM therapeutic classes needs to be reexamined. We evaluated trends in aggregate use and expenditures for all DM therapies among US Medicare Part D beneficiaries from 2012 to 2017.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words